Sierra Oncology president and CEO Dr. Nick Glover tells Mike Ward, Informa Pharma Intelligence insight global director of content, how the company is rebranding itself from its former incarnation ProNAI Therapeutics, armed with two in-licensed assets focused on DNA damage repair (DDR) and USD 100 million in the bank.
Sierra Oncology president and CEO Dr. Nick Glover explains how the company is rebranding itself from its former incarnation ProNAI Therapeutics.
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: